Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results

BACKGROUND: Poly (ADP‐ribose) polymerase (PARP) inhibitors (PARPi) are approved for the treatment of various solid tumors. In gastric cancer, genes commonly harbor mutations in the homologous recombination DNA repair pathway, potentially increasing sensitivity to PARPi. Pamiparib (BGB‐290) is a smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardiello, Fortunato, Bang, Yung‐Jue, Cervantes, Andrés, Dvorkin, Mikhail, Lopez, Charles D., Metges, Jean‐Philippe, Sánchez Ruiz, Antonio, Calvo, Mariona, Strickland, Andrew H., Kannourakis, George, Muro, Kei, Kawakami, Hisato, Wei, Jia, Borg, Christophe, Zhu, Zhaoyin, Gupta, Neal, Pelham, Robert J., Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315793/
https://www.ncbi.nlm.nih.gov/pubmed/37260158
http://dx.doi.org/10.1002/cam4.5997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315793/
https://www.ncbi.nlm.nih.gov/pubmed/37260158
http://dx.doi.org/10.1002/cam4.5997

Ejemplares similares